Posted on 25/10/05
Demand for bird-flu drug causes maker to halt sales
OTTAWA, TORONTO -- Roche Canada has taken the highly unusual step of halting the sale of Tamiflu, thought to be the best defence against an avian influenza pandemic, after the drug maker experienced a higher-than-normal demand for the antiviral medication.
The full text of this article has 730 words.
To continue reading this article, you will need to purchase this article.
Already have a member account? Login now
Pay-Per-View Offers To read the complete article, select one of the following options
Purchasing from globeandmail.com is quick and secure.
